The quantity field is empty. Please enter a quantity of 1 or more to add items to your cart.
Description
Overview
Recombinant, human angiogenin expressed in E. coli. Exhibits angiogenic and ribonucleolytic activities. Enhances the ability of endothelial cells to digest extracellular matrix components and degrade basement membrane. Has been shown to stimulate capillary and umbilical vein endothelial cells to produce DAG and secrete prostacyclin by phospholipase activation. Biological activity: 1.0 µg protein produces an absorbance change at 260 nm of approximately 2.0 - 3.0 as measured by yeast tRNA ribonucleolytic activity.
Catalogue Number
175600
Brand Family
Calbiochem®
References
References
Leland, P.A., et al. 2002. Biochemistry41, 1343. Hatzi, E., et al. 2000. Biochem. Biophys. Res. Commun. 267, 719. Hu, G., et al. 1994. Proc. Natl. Acad. Sci. USA91, 12096. Lee, F.S., and Vallee, B.L. 1989. Biochem. Biophys. Res. Commun.161, 121. Kurachi, R., et al. 1985. Biochemistry24, 5494.
Product Information
Form
Solid
Formulation
Lyophilized from sterile-filtered PBS containing 50 µg BSA/µg Angiogenin.
Applications
Biological Information
Biological activity
≥1.0 µg protein produces an absorbance change at 260 nm of ~2.0-3.0 as measured based upon its ribonucleolytic activity toward Yeast tRNA.
Purity
≥95% by SDS-PAGE
Physicochemical Information
Contaminants
Endotoxins: ≤100 pg/µg Angiogenin
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code
Ambient Temperature Only
Toxicity
Standard Handling
Storage
≤ -70°C
Do not freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to months at -70°C. Avoid freeze/thaw cycles of solutions.
Canadian export regulations
Due to the country and/or U.S. state of origin of the animal material used in this product, this product may not be exported to Canada.
Leland, P.A., et al. 2002. Biochemistry41, 1343. Hatzi, E., et al. 2000. Biochem. Biophys. Res. Commun. 267, 719. Hu, G., et al. 1994. Proc. Natl. Acad. Sci. USA91, 12096. Lee, F.S., and Vallee, B.L. 1989. Biochem. Biophys. Res. Commun.161, 121. Kurachi, R., et al. 1985. Biochemistry24, 5494.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
20-November-2009 JSW
Description
Recombinant, human angiogenin expressed in E. coli. A 14 kDa protein with angeogenic and ribonucleolytic activities. Enhances the proteolytic and fibrinolytic activities of endothelial cells. Also, stimulates the endothelial cell invasion of Matrigel basement membrane. Has been shown to stimulate capillary and umbilical vein endothelial cells to produce DAG and secrete prostacyclin by phospholipase activation.
Form
Solid
Formulation
Lyophilized from sterile-filtered PBS containing 50 µg BSA/µg Angiogenin.
Purity
≥95% by SDS-PAGE
Contaminants
Endotoxins: ≤100 pg/µg Angiogenin
Biological activity
≥1.0 µg protein produces an absorbance change at 260 nm of ~2.0-3.0 as measured based upon its ribonucleolytic activity toward Yeast tRNA.
Solubility
Reconstitute to a concentration ≥1 µg/ml with sterile PBS containing ≥0.1% HSA or BSA.
Storage
≤ -70°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to months at -70°C. Avoid freeze/thaw cycles of solutions.
Toxicity
Standard Handling
References
Leland, P.A., et al. 2002. Biochemistry41, 1343. Hatzi, E., et al. 2000. Biochem. Biophys. Res. Commun. 267, 719. Hu, G., et al. 1994. Proc. Natl. Acad. Sci. USA91, 12096. Lee, F.S., and Vallee, B.L. 1989. Biochem. Biophys. Res. Commun.161, 121. Kurachi, R., et al. 1985. Biochemistry24, 5494.